文章：

急性髓系白血病患者生存率的持续改善：期望寿命损失的应用

Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life

原文发布日期：2016-02-05

DOI: 10.1038/bcj.2016.3

类型: Original Article

开放获取: 是

英文摘要：

We evaluated temporal trends in survival of Swedish acute myeloid leukemia (AML) patients diagnosed between 1973 and 2011 using relative survival ratios (RSRs) and a measure called the loss in expectation of life (LEL). RSRs increased most for patients <60 years at diagnosis during the first calendar periods, but between 1997–2005 and 2006–2011 the most pronounced increase was for those aged 61–70 years at diagnosis; RSR changed from 0.16 (95% confidence interval (CI): 0.13–0.19) to 0.28 (95% CI: 0.23–0.33), respectively. The LEL for males aged 35 years at diagnosis was 41.0 (95% CI: 40.1–41.8) years in 1975 and 19.5 (95% CI: 16.4–22.5) years in 2011. For males aged 65 years, the corresponding figures were 13.8 (95% CI: 13.7–14.0) and 12.0 (95% CI: 11.3–12.8). Conditional LEL estimates suggested that patients who survive 5 years postdiagnosis have shorter remaining lifespan than the general population. The proportion of expected life lost (PELL) suggested that male 65-year-old patients lost 75% of their life expectancy in 2005 and 66% if they were diagnosed in 2011. Survival continued to increase to 2011, with larger improvements in those aged 61–70 years at diagnosis. The LEL and PELL are intuitive measures that may be useful in communicating survival statistics to patients, clinicians and health-care providers.

摘要翻译： 

我们采用相对生存比（RSR）及期望寿命损失年数（LEL）指标，对1973年至2011年间确诊的瑞典急性髓系白血病（AML）患者的生存趋势进行评估。在早期研究阶段，确诊年龄小于60岁患者的RSR增幅最为显著，但在1997–2005年与2006–2011年期间，61–70岁确诊患者的改善最为突出：其RSR分别从0.16（95%置信区间[CI]：0.13–0.19）升至0.28（95% CI：0.23–0.33）。1975年确诊的35岁男性患者LEL为41.0年（95% CI：40.1–41.8），至201年降至19.5年（95% CI：16.4–22.5）；65岁男性患者的LEL则从13.8年（95% CI：13.7–14.0）降至12.0年（95% CI：11.3–12.8）。条件性LEL评估显示，确诊后存活5年的患者其剩余寿命仍短于普通人群。预期寿命损失比例（PELL）指标表明：2005年确诊的65岁男性患者其预期寿命损失达75%，而2011年确诊者这一比例降至66%。截至2011年，患者生存率持续提升，其中61–70岁确诊群体的改善幅度尤为显著。LEL与PELL作为直观的评估指标，有助于向患者、临床医师及医疗保健提供者传达生存统计数据。

原文链接：

Continued improvement in survival of acute myeloid leukemia patients: an application of the loss in expectation of life